Increasing Prevalence of Cancer
The rising global incidence of cancer is a key driver of growth in the Germanium-68/gallium-68 generator market. According to the World Cancer Research Fund, prostate cancer ranks as the fourth most common cancer worldwide and the second most common among men. In 2024, there were 1,467,854 new cases of prostate cancer. The United States reported the highest number of cases (230,125), followed by China (134,156), Japan (104,318), Brazil (102,519), Germany (65,269), metropolitan France (57,357), the United Kingdom (55,485), Russia (52,712), Italy (38,180), and India (37,948). Further, as reported by the American Cancer Society, prostate cancer ranks first among male cancers in 118 countries. Globally, it is second only to lung cancer in terms of diagnoses among men, and in 66% of the world, it is the leading cancer affecting males.
The growing awareness of cancer in developing regions is driving greater demand for gallium-68-based PET imaging. As PET imaging becomes more widely adopted for cancer detection and management, the need for Germanium-68/gallium-68 generators is rising, supporting market expansion. As cancer care continues to evolve, the demand for efficient and reliable radionuclide production systems is expected to accelerate, fueling the global growth of the Germanium-68/gallium-68 generator market.
Regulatory Progress and DMF Amendment Approval
The growth of the global Germanium-68 Gallium-68 generator market is being significantly boosted by ongoing regulatory progress and the streamlined approval of Drug Master File (DMF) amendments. Regulatory agencies such as the U.S. FDA and EMA have increasingly recognized the clinical value of Gallium-68-labeled radiopharmaceuticals in precision diagnostics, particularly in oncology and neurology.
For instance, March 2021: Eckert & Ziegler Radiopharma GmbH had successfully submitted an amendment to their Drug Master File (DMF) to the U.S. Food and Drug Administration for GalliaPharm. Their proprietary Ge-68/Ga-68 generator from available in sizes of up to 100 mCi with a shelf-life of 12 months or for a maximum of 700 elutions. Gallium-68 from GalliaPharm is used for the preparation of diagnostic imaging drugs in Positron Emission Tomography (PET).
Moreover, in June 2020, Curium filed the first stand-alone Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) and also filed an Active Substance Master File (ASMF) with the European Medicines Agency (EMA) for Germanium-68. Curium’s Germanium-68 Ultra is purity characterized, validated, manufactured, and controlled under 21 CFR 211 Current Good Manufacturing Practice (cGMP) for Finished Pharmaceuticals at its registered drug manufacturing facility. There are two primary uses of Germanium-68: for the production of calibration sources for Positron Emission Tomography (PET) scanners and the manufacture of Germanium-68/Gallium-68 generators, which provide a Gallium-68 positron source for radiopharmaceuticals used in PET imaging.
This recognition has led to faster review timelines, clearer regulatory pathways, and more supportive frameworks for manufacturers. The approval of DMF amendments, especially those related to process improvements, quality enhancements, and expanded production capacities, has enabled companies to respond swiftly to rising demand while maintaining compliance with international quality standards. As a result, the regulatory landscape is becoming increasingly favorable, reducing market entry barriers and encouraging investment and innovation across the Germanium-68 Gallium-68 supply chain.
Rising demand for positron emission tomography (PET) imaging
The rising demand for positron emission tomography (PET) imaging is playing a pivotal role in driving the growth of the global germanium-68/gallium-68 (Ge-68/Ga-68) generator market. PET imaging has emerged as an indispensable diagnostic tool, particularly in oncology. Its ability to provide real-time, high-resolution metabolic and functional imaging makes it invaluable for early disease diagnosis, staging, and monitoring treatment response. Gallium-68, a versatile radioisotope widely used in PET scans, is efficiently produced using Ge-68/Ga-68 generators, which serve as a stable, long-lasting source of the isotope. These generators are preferred in clinical and research settings due to their convenience, consistent Ga-68 yield, and reduced dependency on costly cyclotron facilities.
As healthcare systems across developed and emerging economies increasingly integrate advanced imaging technologies, the demand for Ga-68-labeled radiopharmaceuticals continues to rise. This trend is further amplified by the growing adoption of precision medicine, where PET imaging plays a crucial role in personalized treatment strategies. Beyond diagnostics, Ga-68 is gaining traction in targeted radionuclide therapy, particularly in theranostics—a combination of therapy and diagnostics where it is used to both identify and treat cancer cells. The continuous development of novel Ga-68-based radiopharmaceuticals, along with improvements in generator technology, is expanding its clinical applications and reinforcing market growth.
Looking ahead, the Ge-68/Ga-68 generator market is expected to experience sustained expansion, supported by ongoing advancements in nuclear medicine and the increasing emphasis on non-invasive, accurate diagnostic solutions. With PET imaging becoming a cornerstone of modern healthcare, the reliance on Ge-68/Ga-68 generators is set to grow, ensuring their critical role in meeting the evolving demands of medical diagnostics and therapeutic innovation.
Increasing investment in nuclear medicine infrastructure
The growing investment in nuclear medicine infrastructure worldwide is significantly driving the demand for germanium-68/gallium-68 (Ge-68/Ga-68) generators, a critical component in modern radiopharmaceutical production. Governments and private healthcare institutions are expanding nuclear medicine facilities, equipping hospitals with advanced PET/CT scanners, and establishing radiopharmaceutical production centers to meet the rising need for precision diagnostics. These investments enhance the accessibility of Ga-68, a key radioisotope used in PET imaging, particularly for oncology, neurology, and cardiology applications. As more healthcare facilities adopt Ga-68-based radiopharmaceuticals, the reliance on Ge-68/Ga-68 generators which provide a convenient, on-site source of the isotope has increased substantially.
The expansion of nuclear medicine infrastructure is further supported by collaborations between research institutions, pharmaceutical companies, and regulatory bodies to streamline the production and approval of novel radiopharmaceuticals. Countries with emerging healthcare systems are also investing in nuclear medicine capabilities, creating new opportunities for Ge-68/Ga-68 generator suppliers. Additionally, the integration of theranostics—a combination of diagnostics and targeted radionuclide therapy into clinical practice is accelerating demand for Ga-68, reinforcing the importance of reliable isotope supply chains. With continued advancements in radiopharmaceutical development and increasing adoption of PET imaging, the Ge-68/Ga-68 generator market is poised for long-term growth.
As nuclear medicine becomes a cornerstone of modern healthcare, sustained infrastructure investments will ensure the widespread availability of Ga-68, further solidifying the role of Ge-68/Ga-68 generators in supporting diagnostic and therapeutic advancements. This trend underscores the market's potential for expansion, driven by the global shift toward more sophisticated and accessible nuclear medicine solutions.
